Drug failure in the clinic is most often attributed to either unforeseen toxicity or a lack of demonstrated efficacy.Learn More
Drug failure in the clinic is most often attributed to either unforeseen toxicity or a lack of demonstrated efficacy. Thus, predictive in vitro models that more accurately reflect in vivo disease states can inform the preclinical processes of drug discovery and development ensuring higher success rate in the eventual clinical setting. CDI’s iCell and MyCell products offer a wide range of innate, engineered, and induced disease models for screening, hit-to-lead, and lead optimization efforts. The cells are amenable to gene modulation and culture in high-density multiwell plates. iCell and MyCell products have been used in high-throughput screens across various disease areas including infectious disease, neurological disorders, diabetes, and cardiomyopathies.
- Applying Transfection Technologies to Create Novel Screening Models. Cellular Dynamics Application Note.
- Robers M and Jarecki B. (2014) Efficiently Build Relevant In Vitro Models Using Human Stem Cell-derived Tissue Cells, High Performance Transfection and Novel Multiplexed Reporter Techniques. Promega/Cellular Dynamics Webinar.
- Anson B. (2015) Building Richer Assays: iPSC-derived Tissue Cells Are a Powerful Addition to the Biologist’s Tool Box. GEN 35(2).
- 1536-well Screening Assays with iCell Cardiomyocytes2. Cellular Dynamics Product News.